Numinus offers psychedelic-assisted psychotherapy, utilizing methods such as Ketamine-Assisted Therapy and Transcranial Magnetic Stimulation (TMS) to provide effective treatment for mental health conditions that do not respond to traditional therapies. The company also provides accredited training for healthcare providers, enhancing the availability of evidence-based psychedelic therapy in clinical settings.
Funding
Funding not disclosed
Founders
Product
Problem
Many individuals do not respond to conventional mental health therapies, creating a need for alternative treatment options. Access to specialized psychedelic-assisted therapy and accredited training for healthcare providers remains limited.
Solution
Numinus provides integrated mental health care through evidence-based practices, including psychedelic-assisted therapy such as Ketamine-Assisted Therapy and Transcranial Magnetic Stimulation (TMS). The company specializes in alternative therapies for individuals who have not found relief through traditional methods. Numinus also offers accredited training programs for licensed and non-licensed healthcare providers, increasing the availability of these therapies in clinical settings. By combining research-backed treatments with expert support, Numinus aims to advance a new era of wellness and provide human-centered care.
Target Audience
Numinus serves individuals seeking alternative mental health treatments, as well as licensed and non-licensed healthcare providers looking to expand their expertise in psychedelic-assisted therapies.
Features
- Psychiatry services including diagnosis and medication management
- Ketamine-assisted therapy for treatment-resistant depression and other mental health conditions
- Transcranial Magnetic Stimulation (TMS) as a non-invasive treatment option
- Therapy services with licensed mental health professionals
- Psychedelic therapy options
- Accredited training programs for healthcare providers in psychedelic-assisted therapy
- Clinical trials to advance mental health treatments